The oral cavity is an ideal-site for small molecule, nutrient/nutraceutical delivery to the central nervous system (CNS) and systemic circulation due to the highly-vascularized, oral mucosa, near-neutral pH conditions, close proximity to the brain, and avoidance of gastric degradation and the first-pass effect. The rich-blood supply of the oral mucosa and “sticky”, mucoadhesive properties of this novel, saccharide-based, delivery system allows for the efficient absorption of small molecules across several highly-vascularized surfaces including the gingival, sublingual, soft-palatal, and buccal mucosa. Herein, I introduce a novel, saccharide-based, food-form, palatable, easy-to-administer, oral delivery system that attaches to these four, highly-absorptive surfaces for a longer contact-duration than current orally-available formulas resulting in greater, small molecule bioavailability, and a more rapid, therapeutic effect. This invention represents the next-generation in optimized, highly-efficacious, small molecule delivery systems for CNS-related conditions that moves one-step closer in approximating intravenous injection in systemic bioavailability and therapeutic onset.
